ATE391791T1 - Membran penetrierende peptide und deren anwendungen - Google Patents

Membran penetrierende peptide und deren anwendungen

Info

Publication number
ATE391791T1
ATE391791T1 AT01964392T AT01964392T ATE391791T1 AT E391791 T1 ATE391791 T1 AT E391791T1 AT 01964392 T AT01964392 T AT 01964392T AT 01964392 T AT01964392 T AT 01964392T AT E391791 T1 ATE391791 T1 AT E391791T1
Authority
AT
Austria
Prior art keywords
penetrating peptides
membrane
applications
interest
membrane penetrating
Prior art date
Application number
AT01964392T
Other languages
English (en)
Inventor
Yong Guo
Clarence Morse
Zhengbin Yao
George Keesler
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0103110.3A external-priority patent/GB0103110D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE391791T1 publication Critical patent/ATE391791T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
AT01964392T 2000-08-25 2001-08-23 Membran penetrierende peptide und deren anwendungen ATE391791T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22764700P 2000-08-25 2000-08-25
GBGB0103110.3A GB0103110D0 (en) 2000-08-25 2001-02-07 A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1

Publications (1)

Publication Number Publication Date
ATE391791T1 true ATE391791T1 (de) 2008-04-15

Family

ID=26245698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964392T ATE391791T1 (de) 2000-08-25 2001-08-23 Membran penetrierende peptide und deren anwendungen

Country Status (9)

Country Link
EP (1) EP1360311B1 (de)
AT (1) ATE391791T1 (de)
AU (1) AU8524901A (de)
CA (1) CA2420350C (de)
IL (1) IL154589A0 (de)
MX (1) MXPA03001622A (de)
NO (1) NO332050B1 (de)
NZ (1) NZ524386A (de)
WO (1) WO2002018572A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086927A1 (en) 1995-11-01 2003-05-08 University Of Southern California Expression of cyclin G1 in tumors
WO1998044938A1 (en) 1997-04-10 1998-10-15 University Of Southern California Modified proteins which bind extracellular matrix components
FR2781674B1 (fr) * 1998-07-31 2002-06-28 Inst Nat Sante Rech Med Utilisation de nouveaux agents inducteurs de mort cellulaire en synergie avec les interferons
EP1146869A2 (de) 1999-01-27 2001-10-24 University Of South Florida Inhibierung der stat3 signaltransduktion für krebsbehandlung
WO2003062398A2 (en) * 2002-01-23 2003-07-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services NEW TUMOR SUPPRESSOR GENE, p28ING5
WO2003064609A2 (en) * 2002-01-29 2003-08-07 Aventis Pasteur, Ltd. Targeted immunogens
KR20030078115A (ko) * 2002-03-28 2003-10-08 (주)코아바이오텍 펩타이드 유전자 전달매체 및 이를 이용한 유전자 전달 방법
WO2003097671A1 (en) * 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20070178066A1 (en) 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
MXPA06007574A (es) * 2003-12-31 2007-04-17 Sanofi Pasteur Inc Inmunogenos dirigidos.
US8044019B2 (en) 2005-10-28 2011-10-25 Mitsubishi Tanabe Pharma Corporation Cell penetrating peptide
CN101374860A (zh) * 2005-12-23 2009-02-25 技术转让合伙人公司 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
JP2011514160A (ja) 2008-02-21 2011-05-06 バーナム インスティテュート フォー メディカル リサーチ Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物
US8710005B2 (en) 2009-04-10 2014-04-29 Toagosei Co., Ltd. Neuronal differentiation-inducing peptide and use thereof
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
JP5858285B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメント及びその利用
JP5858284B2 (ja) * 2009-07-29 2016-02-10 東亞合成株式会社 キャリアペプチドフラグメントとその利用
US8673845B2 (en) 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
US8673846B2 (en) 2009-11-02 2014-03-18 Toagosei Co. Ltd. Cell proliferation-promoting peptide and use thereof
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
KR101671114B1 (ko) 2015-06-26 2016-10-31 충북대학교 산학협력단 Ｕｌｋ２로부터 유래된 핵 위치화 신호 펩타이드 및 이의 용도
JP2024530931A (ja) * 2021-08-06 2024-08-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ミスフォールドタンパク質の治療及び予防のための組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962415A (en) * 1996-09-20 1999-10-05 Bristol-Myers Squibb Co. Compositions comprising a peptide inhibitor of nuclear protein translocation and an immunosuppressant and methods of use thereof
WO1998049325A1 (en) * 1997-04-28 1998-11-05 Mcgill University Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
SE9801055D0 (sv) * 1998-03-25 1998-03-25 Inst Of Molecul & Cell Biology Use of growth hormone binding protein (GHBP)
EP1235914A2 (de) * 1999-11-24 2002-09-04 Joseph Rosenecker Polypeptide, die multimere von kern-signallokalisierungs- oder proteintransfer- domänen enthalten und ihre verwendung zum transfer biologischer moleküle in zellen
AU2001275423B2 (en) * 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes

Also Published As

Publication number Publication date
NZ524386A (en) 2005-10-28
CA2420350C (en) 2010-07-13
EP1360311B1 (de) 2008-04-09
NO20030856L (no) 2003-04-24
NO20030856D0 (no) 2003-02-24
CA2420350A1 (en) 2002-03-07
NO332050B1 (no) 2012-06-11
MXPA03001622A (es) 2004-09-06
WO2002018572A2 (en) 2002-03-07
AU8524901A (en) 2002-03-13
EP1360311A2 (de) 2003-11-12
IL154589A0 (en) 2003-09-17
WO2002018572A3 (en) 2003-09-12

Similar Documents

Publication Publication Date Title
ATE391791T1 (de) Membran penetrierende peptide und deren anwendungen
BR0113477A (pt) Peptìdios de penetração em membranas e usos dos mesmos
HUP0301842A2 (hu) Laktám vegyület, a vegyületet tartalmazó gyógyszerkészítmény és alkalmazása gyógyszerkészítmény elżállítására
EA200500644A1 (ru) Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
EP1019365A4 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
HUP9902952A1 (hu) Ionos komplex formájú, vízoldható gyógyászati készítmény és alkalmazása
BR9813740A (pt) Teriparatìdeo cristalino
EA201070548A1 (ru) Производные кератина и способы их получения
DE60043620D1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
NO20031159D0 (no) Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner
ATE398630T1 (de) Zyklische conotoxin-peptide
TR200401793T4 (tr) Perindopril tuzu ve bunu içeren farmasötik bileşimler.
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
NO20031860D0 (no) Kahalaolid F
SG10201803541TA (en) Biologically active c-terminal arginine-containing peptides
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE482975T1 (de) Nukleinsäuremoleküle zur kodierung cyclisierbare aminosäuresequenzen
AU2002326070A1 (en) Peyers's patch and/or m-celle targeting ligands
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
ATE491719T1 (de) Peptidinhibitoren gegen den eintritt von hiv in zellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties